Esperoct
Product Specs | Description |
---|---|
Manufacturer Name | Novo Nordisk |
Description | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is a recombinant analogue of human coagulation FVIII conjugated with a 40-kDa polyethylene glycol (PEG) molecule. |
Indications for Adults: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
Indications for Children: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
Contraindications Nutrient in Cell Culture | You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins |
Stabilizer in Final Formulation | Sodium chloride, L-histidine, sucrose, polysorbate 80, L-methionine, and calcium chloride |
Viral Safety Process | 20 nm filtration, detergent treatment |
Product Half-Life | Children (1-<6 years): 14.7 (27) hours Children (6-<12 years): 13.8 (32) hours Adolescents (12-<18 years): 17.4 (39) hours Adults (>18 years): 21.7 (33) hours |
Product Recovery Percentage Mean incremental recovery IR (IU/dL per IU/kg) | Children (1-<6 years): 1.82 (32) Children (6-<12 years): 1.67 (22) Adolescents (12-<18 years): 2.45 (16) Adults (>18 years): 2.53 (24) |
Storage Requirements/Shelf Life |
|
Nominal Vial Size & Diluent Volume | 500, 1000, 1500, 2000, 3000 IU/4mL of saline diluent |